PQ (0.4) — Competitive Intelligence Brief

PQ (0.4) (PQ (0.4)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 8-aminoquinoline. Area: Infectious Diseases.

phase 3 8-aminoquinoline Heme Infectious Diseases Small molecule

Target snapshot

PQ (0.4) (PQ (0.4)) — London School of Hygiene and Tropical Medicine. PQ (0.4) is an antimalarial drug that works by disrupting the parasite's ability to metabolize heme, leading to its death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PQ (0.4) TARGET	PQ (0.4)	London School of Hygiene and Tropical Medicine	phase 3	8-aminoquinoline	Heme
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
artesunate sachets	artesunate sachets	Pfizer	marketed	Artemisinin derivative	Plasmodium parasites (multiple targets including heme and parasite proteins)
Atovaquone Proguanil and Artesunate Pyronaridine	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
Mefloquine and Dihydroartemisinin-piperaquine	Mefloquine and Dihydroartemisinin-piperaquine	University of Oxford	marketed	Antimalarial combination	Parasite heme polymerase (mefloquine); parasite proteins and lipids (dihydroartemisinin); hemozoin (piperaquine)
Dihydroartemisinine-piperaquine	Dihydroartemisinine-piperaquine	Ministry of Public Health, Democratic Republic of the Congo	marketed	Artemisinin-based combination therapy (ACT)	Malaria parasite (Plasmodium species); multiple parasite targets including heme detoxification pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (8-aminoquinoline class)

1. GlaxoSmithKline · 1 drug in this class
2. London School of Hygiene and Tropical Medicine · 1 drug in this class
3. State University of New York - Upstate Medical University · 1 drug in this class